Venus Remedies is currently trading at Rs. 286.05, up by 14.10 points or 5.18% from its previous closing of Rs. 271.95 on the BSE.
The scrip opened at Rs. 274.25 and has touched a high and low of Rs. 291.25 and Rs. 274.25 respectively. So far 6316 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 638.50 on 09-Aug-2021 and a 52 week low of Rs. 225.00 on 09-Mar-2021.
Last one week high and low of the scrip stood at Rs. 293.35 and Rs. 265.00 respectively. The current market cap of the company is Rs. 382.36 crore.
The promoters holding in the company stood at 40.81%, while Institutions and Non-Institutions held 0.28% and 58.91% respectively.
Venus Remedies has received the coveted WHO Good Distribution Practices (GDP) certification from Societe Generale de surveillance (SGS), the world’s reading resting, inspection and certification company, in a resounding endorsement of its quality services throughout the entire supply chain cycle.
Committed to quality in every aspect of its services right from the manufacturing stage to delivery of products to end-customers, the company has consistently maintained impeccable standards in its distribution operations and processes through proven quality management systems.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers. It has world-class manufacturing facilities in Panchkula and Baddi (in India) and Werne (in Germany) and research and development center in Venus Medicine Research Centre (in India).
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1858.70 |
Dr. Reddys Lab | 1258.55 |
Cipla | 1559.20 |
Lupin | 2198.25 |
Zydus Lifesciences | 1004.00 |
View more.. |